Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Comparison of Consolidation Treatment in Elderly Patients With Acute Myeloid Leukemia: Idarubicin (IDA) Combined With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone

NCT04216771 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.

NCT NCT04216771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04216771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Comparison of Consolidation Treatment in Elderly Patients With Acute Myeloid Leukemia: Idarubicin (IDA) Combined With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone
Lead sponsor
Fujian Medical University
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 31, 2020
Completion date
May 31, 2024
Enrollment
320 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml in remission